Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




LAMP Assay Validated for MRSA in Invasive Samples

By LabMedica International staff writers
Posted on 16 Jun 2017
Staphylococcus aureus is a leading cause of bone and joint infections and one of the most common causative pathogens of bacterial pneumonia in children. More...
An increased risk of mortality from invasive staphylococcal infections has been attributed to methicillin-resistant S. aureus (MRSA).

The detection of pathogens by loop-mediated isothermal amplification (LAMP), which is a rapid, cost-effective, and simple method with high sensitivity, has resolved the major limitations of time-consuming culture-based methods and costly polymerase chain reaction (PCR) molecular techniques.

Molecular microbiologists at the University Hospital of Sant Joan de Déu (Barcelona, Spain) evaluated the analytical and diagnostic performance of the eazyplex MRSA test system for the detection of S. aureus and MRSA in invasive samples such as pleural and synovial fluid, in comparison to the gold standard bacterial culture. A volume of spiked pleural sample (analytical validation) or pleural/synovial fluid (diagnostic validation) was diluted in sterile water and genomic DNA was extracted using the NucliSENS EasyMag system.

The team pipetted 25 mL of a DNA mixture were into the six wells of the eazyplex MRSA strip. This contains a reagent mix and six primers in each cap for the simultaneous but individual amplification of Staphylococcus epidermidis- and S. aureus-specific genes, as well as resistance genes mecA and mecC for the detection of MRSA. Amplification products were generated by isothermal autocycling DNA synthesis and visualized by real-time fluorescence measurement with the Genie II device.

The new system appropriately detected a quality control panel of clinical samples with DNA of methicillin-sensitive S. aureus (MSSA), MRSA, and other pathogens. The limit of detection (LoD) was established at 6.4 × 103 CFU/mL for S. aureus and 1.0 × 104 CFU/mL for MRSA. Diagnostic validation of the eazyplex MRSA assay was performed on 51 prospective clinical invasive samples, resulting in sensitivity and specificity values of 83.3% and 97.8%, respectively, for S. aureus detection. The mean turnaround time was 70 minutes.

The authors concluded that the eazyplex MRSA test system was found to have promising potential as a diagnostic tool for the early detection of S. aureus in samples collected from normally sterile body sites. The study was published on in the June 2017 issue of the International Journal of Infectious Diseases.

Related Links:
University Hospital of Sant Joan de Déu


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Rapid Sepsis Test
SeptiCyte RAPID
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.